CN113166150B - 经取代的黄嘌呤衍生物 - Google Patents

经取代的黄嘌呤衍生物 Download PDF

Info

Publication number
CN113166150B
CN113166150B CN201980081691.3A CN201980081691A CN113166150B CN 113166150 B CN113166150 B CN 113166150B CN 201980081691 A CN201980081691 A CN 201980081691A CN 113166150 B CN113166150 B CN 113166150B
Authority
CN
China
Prior art keywords
disorder
trpc5
mixture
mmol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980081691.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113166150A (zh
Inventor
K·格拉赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyderabad Bioscience Co ltd
Boehringer Ingelheim International GmbH
Original Assignee
Hyderabad Bioscience Co ltd
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyderabad Bioscience Co ltd, Boehringer Ingelheim International GmbH filed Critical Hyderabad Bioscience Co ltd
Publication of CN113166150A publication Critical patent/CN113166150A/zh
Application granted granted Critical
Publication of CN113166150B publication Critical patent/CN113166150B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980081691.3A 2018-12-12 2019-12-10 经取代的黄嘌呤衍生物 Active CN113166150B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18212059.2 2018-12-12
EP18212059 2018-12-12
PCT/EP2019/084373 WO2020120449A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (2)

Publication Number Publication Date
CN113166150A CN113166150A (zh) 2021-07-23
CN113166150B true CN113166150B (zh) 2023-12-01

Family

ID=64665183

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980081691.3A Active CN113166150B (zh) 2018-12-12 2019-12-10 经取代的黄嘌呤衍生物

Country Status (5)

Country Link
US (1) US12291532B2 (cg-RX-API-DMAC7.html)
EP (1) EP3894409B1 (cg-RX-API-DMAC7.html)
JP (1) JP7408662B2 (cg-RX-API-DMAC7.html)
CN (1) CN113166150B (cg-RX-API-DMAC7.html)
WO (1) WO2020120449A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12291532B2 (en) * 2018-12-12 2025-05-06 Boehringer Ingelheim International Gmbh Substituted xanthines as modulators of TRPC5 activity
KR20250141831A (ko) * 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도
WO2024236027A1 (en) * 2023-05-18 2024-11-21 Boehringer Ingelheim International Gmbh 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione for use in the treatment of borderline personality disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143229A (zh) * 2013-03-15 2015-12-09 海德拉生物科学有限公司 取代的黄嘌呤及其使用方法
WO2019011802A1 (en) * 2017-07-11 2019-01-17 Boehringer Ingelheim International Gmbh NEW SUBSTITUTED XANTHINE DERIVATIVES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3180340B1 (en) 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
US12291532B2 (en) * 2018-12-12 2025-05-06 Boehringer Ingelheim International Gmbh Substituted xanthines as modulators of TRPC5 activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143229A (zh) * 2013-03-15 2015-12-09 海德拉生物科学有限公司 取代的黄嘌呤及其使用方法
WO2019011802A1 (en) * 2017-07-11 2019-01-17 Boehringer Ingelheim International Gmbh NEW SUBSTITUTED XANTHINE DERIVATIVES

Also Published As

Publication number Publication date
US20220056032A1 (en) 2022-02-24
US12291532B2 (en) 2025-05-06
JP7408662B2 (ja) 2024-01-05
CN113166150A (zh) 2021-07-23
EP3894409B1 (en) 2023-08-23
WO2020120449A1 (en) 2020-06-18
JP2022512374A (ja) 2022-02-03
EP3894409A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
JP5581318B2 (ja) 神経変性疾患治療用のgsk3−ベータ阻害剤としての4−(ピリジン−4−イル)−1h−(1,3,5)トリアジン−2−オン誘導体
JP7114702B2 (ja) 新規置換キサンチン誘導体
KR101905295B1 (ko) 나프티리딘디온 유도체
WO2023041055A1 (zh) Kif18a抑制剂
JP7408662B2 (ja) 置換キサンタン誘導体
TWI825243B (zh) 新穎之經取代黃嘌呤衍生物
JP6526064B2 (ja) ピリドピリミジンジオン誘導体
WO2014152135A1 (en) Polymorphs and salts of a compound
TW202523331A (zh) 作為sstr4激動劑之(2s,5r)-5-(羥甲基)嗎啉-2-甲醯胺

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant